Drug or intervention
Zoledronic acid Clinical Trials
Studies that test Zoledronic acid, alone, with other treatments or as the comparison.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 39Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
This phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with the immunomodulating drug, Zoledronate, given in…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma
- Trial name
- NCT02508038
- Testing
- TCRαβ+/CD19+ depleted Haploidentical HSCT, Zoledronate
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Wisconsin, Madison
Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
This is a phase Ib/II study evaluating the safety and efficacy of zunsemetinib (ATI-450) with capecitabine in patients with hormone receptor-positive and HER2-negative (HR+/HER2-) metastatic breast cancer (MBC).
- Trial name
- NCT06374459
- Testing
- Zumsemetinib, Capecitabine, Zoledronic acid
- Where
- 3 sites in United States
- Volunteers
- 152 people
- Sponsor
- Washington University School of Medicine
Primary Hyperparathyroidism
Bisphosphonate Prior to Parathyroidectomy in Primary Hyperparathyroidism
This study is a randomized, double-blinded, placebo-controlled trial investigating the effects of zoledronic acid (ZOL) versus placebo in patients with primary hyperparathyroidism (PHPT) undergoing parathyroidectomy (PTX).
- Trial name
- ZOLPHPT (NCT06859580)
- Testing
- Zoledronic acid 4 mg, Natriumklorid 9 mg/ml, Fresenius Kabi
- Where
- Denmark
- Volunteers
- 140 people
- Sponsor
- University of Aarhus
Osteoporosis
Preserving Geriatric Muscle With an Osteoporosis Medication
Our goal is to demonstrate efficacy of the novel agent Denosumab to improve or preserve muscle health, strength, mobility and function in frail older adults.
- Trial name
- NCT06118905
- Testing
- Denosumab 60 MG/ML, Zoledronic Acid 5Mg/Bag 100Ml Infusion
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- Chrissy Kistler
Sarcopenia in Elderly
RANK-ligand Inhibition to Combat Sarcopenia With Underlying Osteoporosis
The objective of this study was to conduct a randomized, double-blind, double-dummy active controlled trial to determine the efficacy of denosumab in treating sarcopenia with underlying osteoporosis.
- Trial name
- NCT06643780
- Testing
- Denosumab, Zolendronic Acid
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Prince of Wales Hospital, Shatin, Hong Kong
Sarcopenia in Elderly
RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients
The objective of this study is to conduct a pragmatic, randomized, double-blind, active-controlled trial to assess the efficacy of receptor activator of nuclear factor-kB ligand (RANKL) inhibition in the treatment of sarcopenia…
- Trial name
- NCT07056478
- Testing
- Denosumab (Prolia), Zoledronic acide (Aclasta)
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Prince of Wales Hospital, Shatin, Hong Kong
Chronic Kidney Disease, Osteoporosis
Pharmacokinetics of Zoledronic Acid in Patients on Dialysis
Osteoporosis is a frequent complication of chronic kidney disease (CKD) on dialysis, with an estimated prevalence of approximately 40%. It is associated with increased fracture risk, reduced quality of life, and higher mortality.
- Conditions
- Chronic Kidney Disease, Osteoporosis, Dialysis
- Trial name
- ZADIAL (NCT07741136)
- Testing
- Zoledronic Acid Injection, 5.0 mg, single dose, Zoledronic Acid Injection, 2.5 mg, single dose
- Where
- Brazil
- Volunteers
- 24 people
- Sponsor
- University of Campinas, Brazil
Postmenopausal Osteoporosis, Postmenopausal Osteopenia
The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation
This study is a prospective, multicenter, open-label, randomized non-inferiority trial comparing intravenous ibandronate and zoledronic acid as sequential therapy after denosumab discontinuation in postmenopausal women with…
- Conditions
- Postmenopausal Osteoporosis, Postmenopausal Osteopenia, Primary Osteoporosis, Osteoporosis
- Trial name
- NCT07406685
- Testing
- Ibandronate IV, Zoledronic acid IV
- Where
- Taiwan
- Volunteers
- 52 people
- Sponsor
- National Taiwan University Hospital
Osteoporosis in Post-menopausal Women
Sequential Treatment With Romosozumab Followed by Denosumab vs. Zoledronic Acid for Gains in HIP BMD
Osteoporosis is associated with a high risk of fractures, disability, loss of independence, and excess mortality. Zoledronic acid is an established first-line treatment in Sweden, but many patients at high fracture risk remain at…
- Trial name
- STRONG-HIP (NCT07772609)
- Testing
- Romosozumab, Zoledronic Acid 5 MG in 5 ML Injection, Calcium 500 mg and Vitamin D3 800 IU
- Where
- 9 sites in Sweden
- Volunteers
- 216 people
- Sponsor
- Sahlgrenska University Hospital
Controlled Type 2 Diabetic Patients With Periodontitis
Clinical and Radiographic Evaluation of Subgingival 1% Metformin Gel Versus 0.05% Zoledronate Gel as an Adjunct to MINST of Intrabony Defects in Controlled Type 2 DM
The present randomized placebo-controlled trial aims to evaluate and compare the clinical and radiographic efficacy of subgingivally delivered 0.05% zoledronate gel and 1% metformin gel as adjuncts to minimally invasive…
- Trial name
- NCT07753317
- Testing
- All participants will receive MINST
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Cairo University
Completed, with results posted
All 96Sarcopenia, Osteoporosis
Muscle Impact of Treating Osteoporosis
Osteosarcopenia is a geriatric musculoskeletal syndrome characterized by co-existence of osteoporosis and sarcopenia (low skeletal muscle mass, strength, and/or functional capacity).
- Trial name
- MITO (NCT05666310)
- Testing
- Denosumab, Zoledronic Acid
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Nami Safai Haeri
Osteoporosis
Denosumab (DMAB) Discontinuation And Switching In Glucocorticoid-Induced Osteoporosis (GIOP): A Pilot Study
Investigators will test the hypothesis that an increase in bone turnover markers (e.g. carboxy-terminal collagen crosslinks (CTX) and P1NP) in patients currently taking chronic glucocorticoids will be attenuated more in those who…
- Trial name
- NCT04177940
- Testing
- DMAB Discontinuation and Switching
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Alabama at Birmingham
Bone Density, Low, Bone Loss
Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa
This protocol is a randomized, double-blind, placebo-controlled clinical trial which aims to investigate the effect of romosozumab on BMD in women with anorexia nervosa.
- Conditions
- Bone Density, Low, Bone Loss, Anorexia Nervosa, Eating Disorders
- Trial name
- NCT04779216
- Testing
- Romosozumab Prefilled Syringe, Zoledronic acid 5 mg
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Karen Klahr Miller, MD
Spinal Cord Injury, Acute Spinal Cord Injury
Prevention of Bone Loss After Acute SCI by Zoledronic Acid
The overall objective of this study is to define an effective therapeutic approach, using currently available medication, to prevent or mitigate the loss of bone mass and bone strength that occurs after acute spinal cord injury.
- Conditions
- Spinal Cord Injury, Acute Spinal Cord Injury, Bone Loss, Osteoporosis
- Trial name
- NCT02325414
- Testing
- Zoledronic acid
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Northwestern University
Bariatric Surgery Candidate, Bone Loss
Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery
Bariatric surgery leads to bone loss and increases fracture risk. This study evaluates whether denosumab can prevent the high-turnover bone loss that occurs after Roux-en-Y Gastric Bypass (RYGB) and sleeve gastrectomy (SG)…
- Trial name
- NCT04087096
- Testing
- Denosumab, Zoledronic Acid
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Massachusetts General Hospital